Related references
Note: Only part of the references are listed.Science v. Ideology in Court: Mifepristone and the US Food and Drug Administration
Wendy K. Mariner
ANNALS OF INTERNAL MEDICINE (2023)
The Mifepristone Case and the Legitimacy of the FDA
Abbe R. Gluck
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
Alliance for Hippocratic Medicine v. FDA - Dobbs's Collateral Consequences for Pharmaceutical Regulation
Patricia J. Zettler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Judicial interference with mifepristone
Margaret Hamburg et al.
SCIENCE (2023)
The New Threat to Abortion Access in the United States-The Comstock Act
I. Glenn Cohen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
The next two decades of mifepristone at FDA: History as destiny
Eli Y. Adashi et al.
CONTRACEPTION (2022)
Pushing Back with Pills - Enhancing Access to Reproductive Health Drugs after Dobbs
Lewis A. Grossman
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Mifepristone, preemption, and public health federalism
Patricia J. Zettler et al.
JOURNAL OF LAW AND THE BIOSCIENCES (2022)
Ensuring Safe Access to Mifepristone During the Pandemic and Beyond
Beatrice L. Brown et al.
ANNALS OF INTERNAL MEDICINE (2021)